Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

SMK-17, a MEK1/2-specific inhibitor, selectively induces apoptosis in β-catenin-mutated tumors.

Scientific reports - 2 Feb 2015

Kiga Masaki, Nakayama Ayako, Shikata Yuki, Sasazawa Yukiko, Murakami Ryo, Nakanishi Toshiyuki, Tashiro Etsu, Imoto Masaya

Abstract excerpt

Although clinical studies have evaluated several MEK1/2 inhibitors, it is unlikely that MEK1/2 inhibitors will be studied clinically. BRAF mutations have been proposed as a responder marker of MEK1/2 inhibitors in a preclinical study. However, current clinical approaches focusing on BRAF mutation...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Butadienes
Share to MAP Kinase Kinase 1
Share to MAP Kinase Kinase 2

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mice, Inbred NOD

Share to Mice, SCID

Share to Nitriles

Share to Sulfonamides

Share to Transcription Factor 7-Like 2 Protein

Source

Open in PubMed Open full text

Identifiers

PMID: 25640451
DOI: 10.1038/srep08155
PMCID: PMC4313120

Genes

BRAF
TCF4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-25640451-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

SMK-17, a MEK1/2-specific inhibitor, selectively induces apoptosis in β-catenin-mutated tumors.PMID 25640451Read ↗

Intrinsic resistance to selumetinib, a selective inhibitor of MEK1/2, by cAMP-dependent protein kinase A activation in human lung and colorectal cancer cells.Semantic proximity Read ↗

RNAi Screening Identifies TAK1 as a Potential Target for the Enhanced Efficacy of Topoisomerase InhibitorsSemantic proximity Read ↗

MEK1/2 inhibition enhances the radiosensitivity of cancer cells by downregulating survival and growth signals mediated by EGFR ligands.Semantic proximity Read ↗

TGFβ signaling sensitizes MEKi-resistant human melanoma to targeted therapy-induced apoptosisSemantic proximity Read ↗

MEK and the inhibitors: from bench to bedsideSemantic proximity Read ↗

β-catenin inhibitors in cancer therapeutics: intricacies and way forwardSemantic proximity Read ↗

Pan-RAF and MEK vertical inhibition enhances therapeutic response in non-V600 BRAF mutant cells.Semantic proximity Read ↗

Targeted engagement of β-catenin-Ikaros complexes in refractory B-cell malignanciesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.